Recurrence, postponing pregnancy, and termination rates after hyperemesis gravidarum: Follow up of the MOTHER study

Kelly Nijsten1,2 | Caitlin Dean1,3 | Loïs M. van der Minnen1 | Joke M. J. Bais4 | Carrie Ris-Stalpers5 | Rik van Eekelen1 | Henk A. Bremer6 | David P. van der Ham7 | Wieteke M. Heidema8 | Anjoke Huisjes9 | Gunilla Kleiverda10 | Simone M. Kuppens11 | Judith O. E. H. van Laar12 | Josje Langenveld13 | Flip van der Made14 | Dimitri Papatsonis15 | Marie-José Pelinck16 | Paula J. Pernet17 | Leonie van Rheenen-Flach18 | Robbert J. Rijnders19 | Hubertina C. J. Scheepers20 | Tatjana Vogelvang21 | Ben W. Mol22 | Tessa J. Roseboom1,2 | Marjette H. Koot9 | Iris J. Grooten1 | Rebecca C. Painter1

1Department of Obstetrics and Gynecology, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
2Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
3Pregnancy Sickness Support, Bodmin, UK
4Department of Obstetrics and Gynecology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands
5Laboratory of Reproductive Biology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
6Department of Obstetrics and Gynecology, Reini de Graaf Hospital, Delft, the Netherlands
7Department of Obstetrics and Gynecology, Martini Hospital, Groningen, the Netherlands
8Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands
9Department of Obstetrics and Gynecology, Gelre Hospital, Apeldoorn, the Netherlands
10Department of Obstetrics and Gynecology, Flevo Hospital, Almere, the Netherlands
11Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, the Netherlands
12Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, the Netherlands
13Department of Obstetrics and Gynecology, Zuyderland Hospital, Heerlen, the Netherlands
14Department of Obstetrics and Gynecology, Franciscus Gasthuis, Rotterdam, the Netherlands
15Department of Obstetrics and Gynecology, Amphia Hospital, Breda, the Netherlands
16Department of Obstetrics and Gynecology, Schepers Hospital, Emmen, the Netherlands
17Department of Obstetrics and Gynecology, Spaarne Gasthuis, Haarlem, the Netherlands
18Department of Obstetrics and Gynecology, OLVG, Amsterdam, the Netherlands
19Department of Obstetrics and Gynecology, Jeroen Bosch Hospital, ’s-Hertogenbosch, the Netherlands
20Department of Obstetrics and Gynecology, Maastricht University Medical Center, Maastricht, the Netherlands
21Department of Obstetrics and Gynecology, Diakonessenhuis, Utrecht, the Netherlands
22Department of Obstetrics and Gynecology, Monash University, Clayton, Victoria, Australia

Abbreviations: CI, confidence interval; HG, hyperemesis gravidarum; IQR, interquartile range; MOTHER, Maternal and Offspring outcomes after Treatment for HyperEmesis by Refeeding; OR, odds ratio; PUQE-24, 24-hour Pregnancy Unique Quantification of Emesis score; RCT, randomized controlled trial; SD, standard deviation.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)
Hyperemesis gravidarum (HG) is a severe complication of pregnancy affecting around 1% of pregnancies globally.\(^1\) HG can cause significant physical and psychological morbidity for mothers.\(^2\) A lack of effective treatment makes HG a challenging condition to manage and therapeutic termination is commonly reported.\(^3,4\)

A history of HG is the single most important risk factor for developing HG.\(^5\) The recurrence rate has been reported to be well above

---

### Key message

Women admitted for hyperemesis gravidarum in a previous pregnancy have a high chance of recurrence (89%) and often postpone subsequent pregnancies (40%). There are also women who considered terminating or actually terminated subsequent pregnancies due to recurrent HG (23%).
baseline risk, but literature shows a wide range varying from 15% to 81%. A recent systematic review failed to produce an aggregate recurrence rate due to the contributing studies’ methodological shortcomings, including poor external validity and significant heterogeneity.

Such a wide risk prediction bracket for a condition with substantial biopsychosocial impacts makes informed decision-making regarding subsequent pregnancies difficult. Patients have expressed a desire for research to provide a definitive recurrence risk and recently this was also recognized as a priority research question by a priority-setting partnership. Furthermore, there is evidence suggesting that early treatment and lifestyle preparation strategies may reduce the overall severity of the condition. For such interventions to be appropriately implemented, the recurrence rate must be understood.

Both overestimating and underestimating the recurrence rate can have substantial impacts on people’s lives. There are reports of families curtailing future pregnancies believing HG is unavoidable as well as reports of women deciding to terminate on the assumption that their risk in a future pregnancy is that of the general population. In this study, we aimed to prospectively measure the self-reported recurrence rate of HG, the postponement of pregnancy because of previous HG, and pregnancies terminated due to recurrent HG. Additionally, we aimed to identify predictive factors associated with an increased risk of HG recurrence, and postponing and terminating subsequent pregnancies.

2 | MATERIAL AND METHODS

This study is a prospective cohort follow-up study of the Maternal and Offspring outcomes after Treatment for HyperEmesis by Refeeding (MOTHER) randomized control trial (RCT) and associated observational cohort.

The original MOTHER RCT assessed whether early enteral tube feeding in addition to standard care for women admitted with HG improved neonatal and maternal outcomes. Women admitted for HG between 5 and 20 weeks of gestation in 19 different hospitals in the Netherlands between 2013 and 2016 were recruited. In total, 115 women were randomized and 100 women, who declined randomization, were recruited to an associated observational cohort. Early enteral tube feeding did not affect maternal and perinatal outcomes, so we combined the RCT and cohort into one study population for this follow-up study. Detailed information about data collection can be found in the original study protocol and earlier published results of the MOTHER RCT.

The MOTHER follow-up study consisted of a single, self-reported, online questionnaire that assessed health and reproductive outcomes after participating in the MOTHER study. Participants who gave consent to be approached for follow-up studies were emailed with a link to the online questionnaire. Both Dutch and English language options were available. In case of no response, a reminder was sent after 1, 3, and 6 weeks. Individual informed consent had been obtained during both the MOTHER and follow-up studies.

For the full questionnaire please see Appendix S1. Women self-reported whether they had conceived again since participating in the MOTHER study. Those who had not had a further pregnancy were asked whether they had curtailed or postponed any future pregnancies due to fear of recurrent HG. For those who had subsequent pregnancies, nausea and vomiting symptoms were assessed with a series of questions regarding the onset of symptoms, hospital admission including duration and frequency, anti-emetic use, and tube feeding. We considered that HG had recurred if vomiting symptoms were reported with multiple HG medication use (two or more, including anti-emetics and corticosteroids, see full list in Appendix S1), weight loss during pregnancy, admission for HG, requiring tube feeding, or symptoms severe enough to affect their life and/or work. The HG definition we used was based on the recently internationally developed WINDSOR HG definition (unpublished results, manuscript currently submitted for publication). Weight loss was reported as lowest weight during pregnancy compared with prepregnancy weight and reported as any weight loss and more than 5% weight loss. We also assessed whether pregnancies had ended as miscarriages or ectopic pregnancies and if women had considered terminating or had terminated their pregnancy due to recurrent HG. Because of ethical considerations, we were unable to verify answers to the questionnaire with medical records. The follow-up questionnaire also included questions about depression, anxiety, and post-traumatic stress disorder symptoms after having HG in the index pregnancy. These results will be discussed in a different manuscript that is currently submitted for publication.

We also assessed if we could identify factors that could predict which women were at increased risk of developing recurrent HG, to postpone subsequent pregnancies, or to terminate or consider terminating subsequent pregnancies because of severe recurrent HG with use of univariable regression analysis. For this analysis, recurrent HG in subsequent pregnancies was broken down into the following outcome measures: being admitted to the hospital, having weight loss, and receiving tube feeding due to recurrent HG in subsequent pregnancies.

We assessed the following possible predictive factors: maternal age, ethnicity, and several measures of HG severity in the index pregnancy, when participating in the MOTHER study. Measures of HG severity in the index pregnancy as predictor variables were: higher symptom severity (measured by the self-reported, validated 24-hour Pregnancy Unique Quantification of Emesis [PUQE-24] score at baseline), lower weight gain at inclusion in the MOTHER study compared with prepregnancy weight, higher total duration of hospital admissions, and admission after the first trimester. The PUQE-24 score can vary from 3 to 15 with a higher score indicating more severe symptoms.

2.1 | Statistical analyses

Continuous variables were presented as means with standard deviations if they were normally distributed, or otherwise presented as
medians with interquartile ranges. Dichotomous and categorical variables were presented as frequencies with percentages. A sensitivity analysis was performed to assess differences in demographic and clinical characteristics of the index pregnancy between participating and non-participating women in this follow-up study. Independent Student’s t test, Mann–Whitney U test, and chi-squared test were used for analyses.

Univariable logistic regression analysis was used to identify possible predictive factors for an increased risk of HG recurrence, or postponing or terminating subsequent pregnancies. Due to the low number of events, we were not able to perform multivariable logistic regression analysis and adjust for confounders.16

As described earlier, we deemed it appropriate to combine the MOTHER RCT and associated observational cohort into one combined study population. However, as this study is a follow up of an RCT, we felt it was necessary, for ethical reasons, to also assess whether there were differences in recurrence, postponement, and termination rates between the RCT arms. Methods and results of these analyses can be found in Appendix S2. Values of \( p \) less than 0.05 were considered statistically significant and SPSS Statistics 26.0 for Windows (IBM Corp., Armonk, NY, USA) was used for analyses.

2.2 Patient and public involvement

Patients have been involved in this research from the inception of the MOTHER study when patients expressed a desire for the research question. The Dutch HG patient charity, Zwangerschapsm isselijkheid en Hyperemesis Gravidarum, was consulted at various points, including piloting the survey questions. Desire for a prospective study to address the recurrence rate of HG is well documented by one of the authors, who is a patient representative (CD)6 and has given patient perspective on the results and interpretation of this study.

2.3 Ethical approval

The MOTHER trial was registered at www.trialregister.nl (NTR4197) and was approved by the research ethics committee of the Amsterdam UMC, location AMC on April 3, 2013. Ethics approval was not required for the follow-up study under the Medical Research Involving Human Subjects Act (reference number W20_066 #20.094).

3 RESULTS

Out of 215 MOTHER participants who had given consent to be contacted for follow-up studies, 190 were approached. Seventy-five participants completed the follow-up survey between March and May 2020. About half of the respondents completed the questionnaire after receiving the initial email invitation (40/75, 53%). Respectively, 11% (8/75), 20% (15/75), and 16% (12/75) of the participants responded after the first, second, and third reminder emails. Two women were excluded because they reported on pregnancies before the index pregnancy and not on subsequent ones in a distinguishable way. Therefore, 73 participants were included for analysis, as shown in Figure 1.

Following the index pregnancy, 38 women (52%) did not get pregnant again. Of them, two-thirds (24/38) stated that this was because of HG, while 14 women stated other reasons (Table 2). Thirty-five women conceived one or more subsequent pregnancies. Of those women, 40% (14/35) had postponed their pregnancy due to HG.

Hyperemesis gravidarum recurred in 88.6% of subsequent pregnancies (Table 2). Of the women with recurrent HG, 54% required...
two or more medications to manage their symptoms, 60% were admitted to hospital for HG and 63% experienced weight loss with an average of −4.5 ± 4.4 kg. One woman terminated her pregnancy and eight women (23%) considered terminating their subsequent pregnancy because of recurrent HG.

In six out of 45 subsequent pregnancies no vomiting symptoms were reported. Of these six pregnancies, one was an ectopic pregnancy and four ended in a miscarriage. Four of these five women went on to have another, successful, pregnancy in which they did experience vomiting symptoms. The fifth woman had three miscarriages in which she developed HG each time.

In univariable regression analysis, we assessed whether there were factors that could predict HG recurrence, postponing, and (consideration of) terminating subsequent pregnancies. Baseline characteristics of women who became pregnant again and were included in the regression analysis are shown in Table S2. Univariable logistic regression analysis showed that having a western background was associated with having weight loss due to recurrent HG in subsequent pregnancies (odds ratio 12.86, 95% CI 1.27–130.54, p = 0.03). No associations were found between maternal age and several measures of HG severity in the index pregnancy, and HG recurrence, and postponing and (consideration of) terminating subsequent pregnancies. (Table 3).

### DISCUSSION

In a well-defined prospective cohort, we found a high HG recurrence rate of 89%. Furthermore, we found high proportions of women who avoided a subsequent pregnancy (33%), postponed their pregnancy (40%), or considered terminating their pregnancy (23%) because of HG. Additionally, we found that having a western background was associated with having weight loss due to recurrent HG in subsequent pregnancies.

Our study found an 89% recurrence rate of HG. A recent systematic review identified five previously published, prospective studies assessing the HG recurrence rate. Four were population database cohorts that used birth registry data and International Classification of Diseases 10th revision (ICD-10) codes to identify HG patients and which reported relatively low recurrence rates between 15% and 26%. Although large populations were included in their study, with the number of HG cases varying from 447 to 33,214, Dean et al. concluded that methods lacked both external validity and internal reliability. While ICD codes may seem an effective method for pregnancy data collection, attempts to validate them for identifying HG have proved unsuccessful. Norwegian researchers found that the Medical Birth Registry and ICD codes were valid for mild, but not for severe, pregnancy sickness or HG. In our study, only 60% of women with HG were admitted in subsequent pregnancies, which would suggest that ICD codes are missing for around 30% of women with recurrent HG in the Dutch system. The fifth study, by Fejzo et al., reported a substantially higher recurrence rate of 81% (46/57 women), but consisted of a self-reported follow up from an online survey of self-selected participants, making it prone to selection bias. Our follow-up survey was also self-reported, but the initial population was recruited with robust inclusion criteria for HG, which provided our study with a greater degree of external validity.

To our knowledge, Fejzo et al. is the only study assessing HG severity in subsequent pregnancies. They reported higher rates of tube feeding than our study (20% vs. 14.3%), but similar admission rates (48% vs. 60%), which is likely a reflection of healthcare system differences between the USA and European countries.

Literature regarding women curtailing pregnancies after developing HG is scarce and heterogenic. Fiaschi et al. found no evidence of women with HG curtailing any future pregnancies compared with women without HG in their population-based cohort study that included 33,214 women with HG. We consider this a surprising finding considering that Heitmann et al. found that 75.7% (159/210 women) of those with severe nausea and vomiting symptoms considered never getting pregnant again. Furthermore, Fejzo et al. reported that 37% (37/100 women) had avoided any further pregnancies due to HG. Our study found that 33% of women curtailed pregnancies due to HG. We also found that 40% of the women who got pregnant again after their index pregnancy postponed their pregnancy due to HG in the past. Poursharif et al. described that 76% (614/808) of participants in their large self-selected online-survey cohort reported a change in personal attitude to future childbearing following an HG pregnancy, including increased spacing of pregnancies or fewer children than previously desired. This phenomenon is also described in a review from Dean et al. reporting on the effect of HG on women's lives and is recognized by our Patient and Public Involvement representatives.

Previous surveys have identified a termination rate for HG between 3% and 15%. Poursharif et al. reported that 6% (49/808

### TABLE 1 Baseline characteristics of women included in this follow-up study

| Baseline characteristics | N = 73 |
|--------------------------|--------|
| Age (years), mean ± SD   | 29.2 ± 4.6 |
| Education level, n (%)   | 40% |
| Primary or secondary     | 27 (37.0%) |
| Higher                   | 29 (39.7%) |
| Ethnicity, n (%)         | 71.2% |
| Western                  | 52 (71.2%) |
| Non-western              | 12 (16.4%) |
| Primigravida at time of MOTHER inclusion, n (%) | 27 (37.0%) |
| HG in pregnancy before MOTHER inclusion, n (%) | 22 (47.8%) |

Note: Data presented with mean ± SD, median (IQR) or frequency (%). Abbreviations: HG, hyperemesis gravidarum; IQR, interquartile range; MOTHER, Maternal and Offspring outcomes after Treatment for HyperEmesis by Refeeding; SD, standard deviation.

A Percentage shown is frequency divided by multigravida at time of MOTHER inclusion.
women) underwent multiple terminations for HG and an additional 13% “almost” terminated their pregnancy due to HG. Although in our study only one woman terminated a pregnancy due to developing HG again, we found that 23% of women considered terminating a pregnancy, which is consistent with a rate of 26.7% (56/210 women) reported in a Scandinavian population. Variation in rates reported may reflect differences in access to treatment and social support around the world. For example, women included in Poursharif et al. were predominantly from the USA, where sick pay and employment rights are not statutory and treatment for HG is expensive. Our study participants are from the Netherlands where treatment is covered by universal healthcare insurance and employees can make use of extended paid sick leave and are protected from termination of contract due to illness. However, 23% of women considering termination of pregnancy due to HG is worryingly high and highlights the importance of early recognition and treatment of symptoms and supportive care.

Our study has several strengths. All participants had well-documented HG during their index pregnancy, which is of benefit compared with previous studies, which relied on hospital admission records, usually only including pregnancies that had led to a delivery. Including patient representatives in the conception and design of the research and interpretation of the results is also a strength, because this has been earlier recognized to improve the quality and relevance of research. Our study also assessed whether subsequent pregnancies were viable and whether measures of HG severity of the index pregnancy can be used as predictive factors of recurrent HG, and postponing and termination rates. These are both recognized as important matters in clinical practice by our patient representatives, especially as, in our study, most women without vomiting symptoms had a non-viable pregnancy.

Our results are limited by the small sample size. Of the cohort of 215 women, 75 (35%) responded, despite our recruitment efforts, and only 35 women (16%) had become pregnant again. Selective participation led to women with more severe symptoms in the index pregnancy being over-represented in the current study, probably leading to selection bias. It is conceivable that those who did not participate in this follow-up study had a lower HG recurrence in subsequent pregnancies, which means that the recurrence rate presented here may be overestimated. Additionally, RCT analyses were hampered by an even smaller sample size, including 24 women who had become pregnant again. Also, the association between having a non-viable pregnancy, which is likely to be affected by the size of our study, with only 6/35 women that became pregnant again having a non-western background. External validity may therefore be limited.

In this follow-up study, data were gathered through a self-reported, non-validated questionnaire, because there is no validated questionnaire available. The nature of some of the included questions could be considered to be subjective. Additionally, there was potential for recall bias on pregnancies experienced up to 7 years before participants completed the questionnaire as subsequent pregnancies could have taken place from 2013 onwards. This may have led to both under- and over-reporting of HG symptoms, although previous studies have shown that self-reporting questionnaires are well validated for reporting on pregnancy.

| TABLE 2 Recurrence, postponing, and termination rates in subsequent pregnancies |
|-----------------------------------------------|
| Subsequent pregnancies | N = 73 |
| Women who experienced a subsequent pregnancy, n (%) | 35 (47.9%) |
| Number of pregnancies after MOTHER study, median (IQR) | 1.0 (1.0–2.0) |
| one pregnancy, n (%) | 26 (74.3%) |
| two pregnancies, n (%) | 8 (22.9%) |
| three or more pregnancies, n (%) | 1 (2.9%) |
| Women who did not become pregnant again due to fear for recurrent HG, n (%) | 24 (32.9%) |
| Time interval between MOTHER and follow-up study participation (years), median (IQR) | 4.5 (4.1–5.0) |

Recurrence rate of HGa

Recurrent of vomiting symptoms, n (%) | 34 (97.1%) |
Gestational age when vomiting started (weeks), median (IQR) | 6.0 (4.0–7.0) |
Used multiple (two or more) HG-related medications, n (%) | 19 (54.3%) |
Was admitted to hospital, n (%) | 21 (60.0%) |
Duration of hospital admissions (days), mean ± SD | 6.5 ± 4.0 |
Had weight loss, n (%)b | 22 (62.9%) |
Had >5% weight loss, n (%) | 16 (45.7%) |
Average weight change (kg), mean ± SDb | −4.2 ± 4.3 |
Received tube feeding, n (%) | 5 (14.3%) |
NVP affected her job, n (%) | 20 (57.1%) |
NVP affected her life, n (%) | 26 (74.3%) |
Had HG, n (%)c | 31 (88.6%) |

Postponed or terminated pregnancies

Postponed a pregnancy due to HG in the past, n (%) | 14 (40.0%) |
Considered terminating a pregnancy due to HG in subsequent pregnancies, n (%) | 8 (22.9%) |
Terminated a pregnancy due to HG in subsequent pregnancies, n (%) | 1 (2.9%) |

Note: Data presented with mean ± SD, median (IQR) or frequency (%). Abbreviations: HG, hyperemesis gravidarum, IQR, interquartile range; MOTHER, Maternal and Offspring outcomes after Treatment for HyperEmesis by Refeeding; NVP, nausea and vomiting in pregnancy; SD, standard deviation.
aHG recurrence rate in any subsequent pregnancy.
bLowest weight during pregnancy minus prepregnancy weight: can be <0 if women lost weight and can be >0 if women gained weight.
cHG defined as: vomiting symptoms with either multiple medication use, hospital admission, weight loss during pregnancy, tube feeding or NVP affecting her job and/or life.

NIJSTEN ET AL.
Our study found a high recurrence rate for HG of 89%. Although it seems plausible that selective attrition has occurred and led to an overestimation, our study suggests that the recurrence rate is more likely to be at the high end of the current available range of 15%–81%. Although such findings may be distressing for women who were hoping future pregnancies would be better, it is important information to give during preconception consultations, so that people are able to make informed decisions about their family planning. Knowing that HG has a very high chance of recurrence allows families not only to plan in advance for childcare and finances, but also to discuss available treatments and the possibility of early interventions, which may make the burden of the condition easier to bear. Finally, it is important that healthcare professionals do not give false hope regarding the chance of recurrence and that they recognize the severe burden of a condition that leads so many women to consider terminating, or to actually terminate their otherwise wanted pregnancies.

### 5 | CONCLUSION

Our study found a high recurrence rate for HG of 89%. Although it seems plausible that selective attrition has occurred and led to an overestimation, our study suggests that the recurrence rate is more likely to be at the high end of the current available range of 15%–81%. Although such findings may be distressing for women who were hoping future pregnancies would be better, it is important information to give during preconception consultations, so that people are able to make informed decisions about their family planning. Knowing that HG has a very high chance of recurrence allows families not only to plan in advance for childcare and finances, but also to discuss available treatments and the possibility of early interventions, which may make the burden of the condition easier to bear. Finally, it is important that healthcare professionals do not give false hope regarding the chance of recurrence and that they recognize the severe burden of a condition that leads so many women to consider terminating, or to actually terminate their otherwise wanted pregnancies.

### CONFLICT OF INTERESTS

BWM reports grants from the National Health and Medical Research Council (NHMRC) outside the submitted work. The rest of the authors have nothing to disclose.

### AUTHOR CONTRIBUTIONS

IJG, TJR, and RCP conceived and designed the MOTHER study. KN and RCP conceived and designed the follow-up study. LMvdM helped develop the online survey tool. KN performed all statistical analyses supervised by RCP and RvE. KN and CD drafted the manuscript. The following authors were responsible for recruitment of, and data collection from the original MOTHER RCT and cohort: JMJB, CR-S, HAB, DPvdH, WMH, AH, GK, SK, JOEHvL, JL, FvdM, DP, M-JP, PJP, LvRF.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from
the principle investigator (r.c.painter@amsterdamumc.nl) upon rea-
sonable request.

ORCID
Kelly Nijsten https://orcid.org/0000-0002-5308-5293
Wieteke M. Heidema https://orcid.org/0000-0003-1653-0885
Ben W. Mol https://orcid.org/0000-0001-8337-550X

REFERENCES
1. Einarson TR, Piwko C, Koren G. Quantifying the global rates of nau-
sea and vomiting of pregnancy: a meta analysis. J Popul Ther Clin Pharmacol. 2013;20:e171-e183.
2. Fiaschi L, Nelson-Piercy C, Gibson J, Szatkowski L, Tata LJ. Adverse maternal and birth outcomes in women admitted to hospital for hyper-
emesis gravidarum: a population-based cohort study. Paediatr Perinat Epidemiol. 2018;32:40-51.
3. Poursarif Har, Korst L, MacGibbon K, Fejzo M, Romero R, Goodwin T. Elective pregnancy termination in a large cohort of women with hyperemesis gravidarum. Contraception. 2007;76:451-455.
4. Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum. Cochrane Database Syst Rev. 2016;(5):CD010607.
5. Fiaschi L, Nelson-Piercy C, Tata LJ. Hospital admission for hyperemesis gravidarum: a nationwide study of occurrence, reoccurrence and risk factors among 8.2 million pregnancies. Hum Reprod. 2016;31:1675-1684.
6. Dean CR, Bruin CM, O’Hara ME, et al. The chance of recurrence of hyperemesis gravidarum: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2020;205:100105. https://doi.org/10.1016/j.ejogrb.2019.100105.
7. Dean CR, Blerva H, Clarke R, et al. A patient-clinician James Lind alliance partnership to identify research priorities for hyperemesis gravidarum. BJM Open. 2021;11:e041254. https://doi.org/10.1136/bmjopen-2020-041254
8. Dean C. Helping women prepare for hyperemesis gravidarum. Br J Midwifery. 2014;22:847-852.
9. Koren G, Maltepe C. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. J Obstet Gynaecol. 2004;24:530-533.
10. Fejzo MS, MacGibbon KW, Romero R, et al. Recurrence risk of hyperemesis gravidarum. Reprod Sci. 2010;17:191A-192A.
11. Nana M, Tydeman F, Bevan G, et al. Hyperemesis gravidarum is associated with increased rates of termination of pregnancy and suicidal ideation: results from a survey completed by >5000 participants [published online ahead of print]. Am J Obstet Gynecol. 2021;https://doi.org/10.1016/j.ajog.2021.03.006
12. Grooten IU, Koot MH, van der Post JAM, et al. Early enteral tube feeding in optimizing treatment of hyperemesis gravidarum: the Maternal and Offspring outcomes after Treatment of Hyperemesis by Refeeding (MOTHER) randomized controlled trial. Am J Clin Nutr. 2017;106:812-820.
13. Grooten IU, Mol BW, van der Post JAM, et al. Early nasogastric tube feeding in optimising treatment for hyperemesis gravidarum: the MOTHER randomised controlled trial (Maternal and Offspring outcomes after Treatment of Hyperemesis by Refeeding). BMC Pregnancy Childbirth. 2016;16:22.
14. Ebrahim N, Maltepe C, Bournissen F, Koren G. Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique Quantification of Emesis (PUQE-24) scale. J Obstet Gynaecol Can. 2009;31:803-807.
15. Lacasse A, Rey E, Ferreira E, Morin C, Bérard A. Validity of a mod-
ified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring index to assess severity of nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2008;198(1):71.e1-71.e7.
16. Peduzzi P, Conato J, Kemper E, Holford TR, Feinstein AR. A simu-
lation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-1379.
17. Trostlad L, Stoltenberg C, Magnus P, Skjaerven R, Irgens L. Recurrence risk in hyperemesis gravidarum. BJOG. 2005;112:1641-1645.
18. Fell DB, Dodds L, Joseph KS, Allen VM, Butler B. Risk factors for hyperemesis gravidarum requiring hospital admission during preg-
nancy. Obstet Gynecol. 2006;2, Part 1;107:277-284.
19. Nurmi M, Rautava P, Gissler M, Vahlberg T, Polo-Kantola P. Recurrence patterns of hyperemesis gravidarum. Am J Obstet Gynecol. 2018;219(5):469.e1-469.e10.
20. Vikanes Å, Magnus P, Vangen S, Lomsdal S, Gribovski A. Hyperemesis gravidarum in the medical birth registry of Norway – a validity study. BMC Pregnancy Childbirth. 2012;12(1):1-6.
21. Fejzo MS, MacGibbon KW, Romero R, Goodwin TM, Mullin PM. Recurrence risk of hyperemesis gravidarum. J Midwifery Womens Health. 2011;56(2):132-136.
22. Rids G, Gleason S, Ridic O. Comparisons of health care sys-
tems in the United States, Germany and Canada. Mater Sociomed. 2012;24(2):112-120.
23. Heitmann K, Nordeng H, Havnen GC, Solheim N, Holst L. The burden of nausea and vomiting during pregnancy: severe impacts on quality of life, daily life functioning and willingness to be-
come pregnant again – results from a cross-sectional study. BMC Pregnancy Childbirth. 2017;17(1):75.
24. Poursarif Har, Korst L, Fejzo M, MacGibbon K, Romero R, Goodwin T. The psychosocial burden of hyperemesis gravidarum. J Perinatol. 2008;28(3):176-181.
25. Dean C, Bannigan K, Marsden J. Reviewing the effect of hyperem-
esis gravidarum on women’s lives and mental health. Br J Midwifery. 2016;24(2):109-119.
26. Mazzotta P, Stewart DE, Koren G, Magee LA. Factors associ-
ated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancy. J Psychosomatic Obstet Gynecol. 2001;22(1):7-12.
27. Rijksinstituut voor Volksgezondheid en Milieu. Gelijke behandeling bij zwangerschap op het werk [Equal treatment at work during pregnancy]. Rijks Health. (in Dutch). 2020. https://www.rijksoverheid.nl/onderwerpen/gelijkhe- deling-op-het-werk/gelijkhe-deling-bij-zwangerschap-op-het-werk
28. Lakani M, Baines R, Bryce M, et al. Patient and public involvement in medical performance processes: a systematic review. Health Expect. 2019;22(2):149-161.
29. Falkegard M, Schirmer H, Lochen ML, Olan P, Acharya G. The va-
lidity of self-reported information about hypertensive disorders of pregnancy in a population-based survey: the Tromso Study. Acta Obstet Gynecol Scand. 2015;94:28-34.

SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section.

How to cite this article: Nijsten K, Dean C, van der Minnen LM, et al. Recurrence, postponing pregnancy, and
termination rates after hyperemesis gravidarum: Follow up of the MOTHER study. Acta Obstet Gynecol Scand. 2021;00:1-8. https://doi.org/10.1111/aogs.14197